{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:07:28Z","timestamp":1779854848351,"version":"3.53.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1097\/cm9.0000000000004124","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:00:10Z","timestamp":1779854410000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparable survival outcomes for secondary and de novo acute myeloid leukemia after haploidentical hematopoietic stem cell transplantation"],"prefix":"10.1097","author":[{"given":"Kehan","family":"Zhang","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Chang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Sun","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeming","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing New Talent Academy, Beijing 101300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"R1-20260527","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12916-024-03395-y","article-title":"Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: A multicentre, randomized trial","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"key":"R2-20260527","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/ijc.35125","article-title":"Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China","volume":"155","author":"Dou","year":"2024","journal-title":"Int J Cancer"},{"key":"R3-20260527","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-023-01450-4","article-title":"Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: A study from the ALWP\/EBMT","volume":"16","author":"Nagler","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R4-20260527","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hon.3160","article-title":"Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry","volume":"41","author":"N\u00fa\u00f1ez-Torr\u00f3n Stock","year":"2023","journal-title":"Hematol Oncol"},{"key":"R5-20260527","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"R6-20260527","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41409-022-01748-w","article-title":"Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)","volume":"57","author":"Maffini","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R7-20260527","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41409-025-02620-3","article-title":"Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: A study from the ALWP \/EBMT","volume":"60","author":"Nagler","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"R8-20260527","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","article-title":"Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: A prospective multicentre cohort study","volume":"34","author":"Yu","year":"2020","journal-title":"Leukemia"},{"key":"R9-20260527","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","article-title":"Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation","volume":"18","author":"Guo","year":"2021","journal-title":"Cell Mol Immunol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:00:13Z","timestamp":1779854413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":9,"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004124","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2025-05-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}